Applied Pharmaceuticals Innovations
API is one of the largest life sciences commercialization organizations in Canada. We are an industry-funded not-for-profit and we provide end-to-end support for life sciences researchers, businesses, and innovators on their path from idea to commercialization. Learn more about API and their services.
Arch Biopartners
Arch Biopartners is a late-stage clinical trial company focused on preventing inflammation and acute organ injury.
Arch is developing a platform of novel therapeutic drugs, led by LSALT peptide (Metablok), that are:
- designed to inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP1) pathway and,
- relevant for common organ injuries and diseases where organ inflammation is an unmet problem with no effective treatments in the market today.
ABOUT LSALT PEPTIDE
Following our scientists’ identification of DPEP1 as an adhesion receptor in the lungs, kidneys and liver and their discovery that DPEP1 was shown to be the target of LSALT Peptide (Cell 2019). Arch believes that the drug has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role.
In 2023 the company has been working on multiple tasks to further advance the LSALT peptide human trials program, including:
- completed an additional Phase I trial which increased the safe dose limit of LSALT peptide;
- successfully obtained the U.S. FDA’s permission to proceed with a new Phase II trial to prevent cardiac surgery-associated acute kidney injury (CS-AKI).
Previous Phase II and III human trials during the pandemic accelerated Arch’s drug development plans and shortened the path toward the approval and commercialization of LSALT peptide as a potential treatment for organ inflammation. Inflammation in the lungs was a common complication of hospitalized pandemic patients and LSALT peptide was used for the first time in a Phase II trial to treat acute lung inflammation in that setting. Successful results accelerated LSALT peptide’s inclusion in a national Phase III trial in Canada looking for new treatments to treat acute lung inflammation in the later stages of the pandemic.
ARCH BIOPARTNERS APPROACH
Arch has a long history of working closely with the scientific community, universities and research institutions. The company’s mission is to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors.
Find out more about LSALT peptide and Arch Biopartners platform of novel therapeutic drugs.
Association Québécoise des infirmières et intervenants en recherche Clinique (AQIIRC)
AstraZeneca Canada Inc.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases, and Respiratory. The company operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 720 employees across the country and our headquarters are located in Mississauga, Ontario. AstraZeneca is proud to be one of Canada’s top contributors to health sciences research and development, supporting world-class research across the country that aims to advance our scientific knowledge and the care of patients around the world. For more information, please visit the company’s website at www.astrazeneca.ca.